First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

BACKGROUND: Daratumumab was the first monoclonal CD38 antibody with single-agent activity approved for the treatment of multiple myeloma. Moreover, daratumumab demonstrated high response rates in relapsed immunoglobulin light-chain (AL) amyloidosis. PATIENTS AND METHODS: In our single-center retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeryczynski, G., Antlanger, M., Duca, F., Binder-Rodriguez, C., Reiter, T., Simonitsch-Klupp, I., Bonderman, D., Kain, R., Krauth, M.-T., Agis, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937667/
https://www.ncbi.nlm.nih.gov/pubmed/33667762
http://dx.doi.org/10.1016/j.esmoop.2021.100065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937667/
https://www.ncbi.nlm.nih.gov/pubmed/33667762
http://dx.doi.org/10.1016/j.esmoop.2021.100065

Ejemplares similares